KA
Kaitlyn Arsenault (Chief Financial Officer) filed 2 Form 4 reports in the past 24 months (0 purchases, 2 sales, 1 filed past the two-business-day deadline), most often in Skye Bioscience, Inc. (SKYE). The largest single filing was $216K of SKYE (43,206 sh × $4.99, as filed), executed Nov 18 2024. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells · 1 late
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$215K
shares × price, as filed
Last traded
Nov 18 2024
Filed Feb 28 2025
Median ADV $146K across their filed names
Open performance→Volume by month
Buys $0
Sells $215K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
SKYERecent filings
SKYESALE
Skye Bioscience, Inc.
View filing →
$215K43,026 sh × $4.99
Exec Nov 18 2024
Filed Feb 28 2025 · 5:30 PM ET † SKYESALE Skye Bioscience, Inc. View filing → $216K
43,206 sh × $4.99
Exec Nov 18 2024
Filed Nov 19 2024 · 5:30 PM ET